"The license includes certain preference conditions that cap the number of similarphenotypic deals Phylogica may enter into during an 18 month option period.Importantly, Phylogica will retain all commercial rights to exploit any Phylomerpeptides identified in the screens for therapeutic purposes."
18 months post April 2015 license is long gone now. Interesting!! Even if our equity stake is about ~3% in Phoremost, they have subsidiary companies now, so doesn't that mean we have an equity stake in those too? I would think so. Libraries have expanded significantly since 2015. So far...in vitro a big tick. All attention is on what the in vivo data can now bring to the table.
Tony
PYC Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)